Get the Stockscreener App
44.08
7.41%
-3.53
After Hours:
44.08
Crinetics Pharmaceuticals Inc stock is traded at $44.08, with a volume of 915.38K.
It is down -7.41% in the last 24 hours and down -20.36% over the past month.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
See More
Previous Close:
$47.61
Open:
$48.41
24h Volume:
915.38K
Relative Volume:
0.71
Market Cap:
$4.52B
Revenue:
$1.54M
Net Income/Loss:
$-423.10M
P/E Ratio:
-9.7221
EPS:
-4.534
Net Cash Flow:
$-356.03M
1W Performance:
-1.59%
1M Performance:
-20.36%
6M Performance:
+54.78%
1Y Performance:
+25.19%
1-Day Range:
$44.02
$48.41
1-Week Range:
$43.94
$48.58
52-Week Range:
$24.10
$57.99
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Name
Crinetics Pharmaceuticals Inc
Sector
Industry
Phone
858-450-6464
Address
6055 LUSK BLVD., SAN DIEGO, CA
Compare CRNX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
44.08 | 4.88B | 1.54M | -423.10M | -356.03M | -4.534 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-26 | Upgrade | Goldman | Neutral → Buy |
| Jul-10-25 | Initiated | Goldman | Neutral |
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-11-25 | Initiated | TD Cowen | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Peer Perform |
| Jan-22-25 | Upgrade | Jefferies | Hold → Buy |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Jan-16-24 | Initiated | Morgan Stanley | Overweight |
| Dec-21-23 | Initiated | Jefferies | Hold |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-31-23 | Initiated | Oppenheimer | Outperform |
| Apr-24-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Robert W. Baird | Outperform |
| Nov-30-21 | Initiated | JMP Securities | Mkt Outperform |
| Nov-23-21 | Initiated | Evercore ISI | Outperform |
| Jun-18-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-23-19 | Initiated | ROTH Capital | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Aug-13-18 | Initiated | JP Morgan | Neutral |
| Aug-13-18 | Initiated | Leerink Partners | Outperform |
| Aug-13-18 | Initiated | Piper Jaffray | Overweight |
View All
Crinetics Pharmaceuticals Inc Stock (CRNX) Latest News
Candriam S.C.A. Grows Stock Position in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Liquidity Mapping Around (CRNX) Price Events - Stock Traders Daily
Recap Report: Is RSSS affected by consumer sentimentJuly 2025 WrapUp & Target Return Focused Stock Picks - baoquankhu1.vn
Weekly Recap: Is Crinetics Pharmaceuticals Inc exposed to currency risksPortfolio Performance Report & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March - GlobeNewswire
Recap Report: Is Crinetics Pharmaceuticals Inc exposed to currency risksPortfolio Growth Summary & High Conviction Buy Zone Alerts - baoquankhu1.vn
Crinetics Pharmaceuticals, Inc. (CRNX): Investor Outlook On Its 70% Upside Potential - DirectorsTalk Interviews
Analysts Are Bullish on Top Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Stryker (SYK) - The Globe and Mail
Lisanti Capital Growth LLC Purchases New Position in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Momentum Shift: Can Crinetics Pharmaceuticals Inc. stock outperform in a bear marketWeekly Trend Recap & Safe Entry Trade Reports - baoquankhu1.vn
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - The Manila Times
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent Share Price Volatility - Yahoo Finance
Crinetics Pharmaceuticals updates Jeff Knight’s executive title and responsibilities By Investing.com - Investing.com Nigeria
Crinetics Pharmaceuticals updates Jeff Knight’s executive title and responsibilities - Investing.com
Why (CRNX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Pullback Watch: Is Crinetics Pharmaceuticals Inc exposed to currency risks2025 Trade Ideas & Community Verified Trade Alerts - baoquankhu1.vn
Jim Cramer on Crinetics: “That’s a better spec than Aquestive” - MSN
Crinetics Pharmaceuticals, Inc. $CRNX Stock Holdings Boosted by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
Crinetics Starts Pediatric BALANCE CAH Trial As Valuation Gap Persists - Sahm
Crinetics begins phase 2/3 trial of oral CAH treatment in children - Investing.com Nigeria
Crinetics (CRNX) Launches Phase 2/3 Trial for Atumelnant in Pedi - GuruFocus
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH) - The Manila Times
Jim Cramer on Crinetics: “That’s a Better Spec Than Aquestive” - Insider Monkey
Is It Too Late To Consider Crinetics Pharmaceuticals (CRNX) After Strong Multi‑Year Share Gains? - Sahm
Goldman Sachs upgrades Crinetics Pharmaceuticals, Inc. (CRNX) to buy from neutral - MSN
A Look At Crinetics Pharmaceuticals (CRNX) Valuation After Goldman Sachs Upgrade And Palsonify Atumelnant Progress - Sahm
Retail Surge: What is the dividend yield of Crinetics Pharmaceuticals Inc2025 Analyst Calls & Fast Gaining Stock Reports - baoquankhu1.vn
Crinetics Pharmaceuticals exec sells shares worth $195,350 - MSN
Goldman Sachs Upgrades Crinetics Pharmaceuticals, Inc. (CRNX) To Buy From Neutral - Insider Monkey
Hedge Fund Bets: Can Crinetics Pharmaceuticals Inc be recession proofEarnings Risk Summary & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Why Crinetics Pharmaceuticals (CRNX) Is Up 18.2% After Equity Raise and PALSONIFY, Atumelnant Updates - Sahm
Crinetics Pharmaceuticals discovers new SSTR2 non-peptide-drug conjugates - BioWorld MedTech
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Goldman Sachs Upgrades Crinetics Pharmaceuticals (CRNX) - Nasdaq
Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
CRNX Upgraded to 'Buy' by Goldman Sachs with New Price Target of $67 | CRNX Stock News - GuruFocus
Crinetics Shares Rise After Goldman Sachs Upgrade - marketscreener.com
The Goldman Sachs Group Upgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) to Buy - MarketBeat
Crinetics stock rating upgraded by Goldman Sachs on promising CAH drug data - Investing.com Canada
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Equity Raise PALSONIFY Launch And Positive Atumelnant Data - Yahoo Finance
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates - sharewise.com
How Crinetics Pharmaceuticals Inc. stock trades during market volatility2025 Earnings Surprises & Weekly High Return Stock Opportunities - Улправда
Crinetics Pharmaceuticals Inc. (CRNX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Crinetics Pharmaceuticals prices offering at $45.95 per share - MSN
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent Strong Share Price Momentum - Sahm
What risks investors should watch in Crinetics Pharmaceuticals Inc. stockLong Setup & Safe Capital Investment Plans - Улправда
Is Crinetics Pharmaceuticals Inc. stock overvalued by current metricsWeekly Trend Report & High Conviction Trade Alerts - Улправда
Does Crinetics Pharmaceuticals Inc. stock trade at a discount to peersTrade Volume Summary & Technical Pattern Alert System - ulpravda.ru
Gains Report: Does Crinetics Pharmaceuticals Inc. stock trade at a discount to peersJuly 2025 Spike Watch & Safe Capital Preservation Plans - ulpravda.ru
Crinetics Pharmaceuticals Inc Stock (CRNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):